The leader in a field others have abandoned, Alnylam Pharmaceuticals Inc., has been working hard to make the case that its RNA-interference technology is moving beyond buzz-worthy platform status into a near-proven modality that is producing late-stage clinical candidates, with its first NDA filing expected in 2017.
With seven candidates in clinical development, expected to reach nine by year's end, the Cambridge, Mass., firm has met its...